AstraZeneca PLC (STO:AZN)
1,611.00
0.00 (0.00%)
Oct 7, 2025, 5:29 PM CET
AstraZeneca Employees
AstraZeneca had 94,300 employees as of December 31, 2024. The number of employees increased by 4,400 or 4.89% compared to the previous year.
Employees
94,300
Change (1Y)
4,400
Growth (1Y)
4.89%
Revenue / Employee
5.70M SEK
Profits / Employee
836.48K SEK
Market Cap
2,501.22B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Swedish Orphan Biovitrum AB | 1,806 |
Sectra AB | 1,296 |
Getinge AB | 11,791 |
Camurus AB | 256 |
Medicover AB | 47,256 |
Asker Healthcare Group AB | 4,030 |
BioArctic AB | 107 |
AddLife AB | 2,181 |
AstraZeneca News
- 10 hours ago - AstraZeneca (AZN) Reports Success in Phase 3 Hypertension Trial - GuruFocus
- 10 hours ago - AZN: Baxdrostat Shows Promising Results in Phase III Trial - GuruFocus
- 11 hours ago - AstraZeneca succeeds in late-stage trial for blood pressure therapy - Seeking Alpha
- 12 hours ago - Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension - Business Wire
- 16 hours ago - AZN : Baxdrostat Meets Primary Endpoint In Phase III Trial For Treatment-Resistant Hypertension - Nasdaq
- 16 hours ago - AstraZeneca's Baxdrostat meets main goal in high blood pressure study - Reuters
- 1 day ago - AstraZeneca (AZN) Signs $555 Million AI Agreement with Algen to Develop Therapies - GuruFocus
- 1 day ago - AstraZeneca (AZN) Achieves Key Milestones in Breast Cancer Treatment Study - GuruFocus